Vessels encapsulating tumor clusters: a novel efficacy predictor of hepatic arterial infusion chemotherapy in unresectable hepatocellular carcinoma.
Hepatic arterial infusion chemotherapy
Survival
Tumor response
Unresectable hepatocellular carcinoma
Vessels encapsulating tumor clusters
Journal
Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
received:
27
08
2023
accepted:
22
09
2023
medline:
20
11
2023
pubmed:
6
10
2023
entrez:
6
10
2023
Statut:
ppublish
Résumé
Vessels encapsulating tumor clusters (VETC) is a novel vascular pattern structurally and functionally distinct from microvascular invasion (MVI) in hepatocellular carcinoma (HCC). This study aims to explore the prognostic value of VETC in patients receiving hepatic arterial infusion chemotherapy (HAIC) for unresectable HCC. From January 2016 to December 2017, 145 patients receiving HAIC as the initial treatment for unresectable HCC were enrolled and stratified into two groups according to their VETC status. Overall survival (OS), progression-free survival (PFS), overall response rate (ORR), and disease control rate (DCR) were evaluated. The patients were divided into two groups: VETC VETC status correlates remarkably well with the tumor response and long-term survival in patients undergoing HAIC. It may be a promising efficacy predictor and help identify patients who will benefit from HAIC.
Identifiants
pubmed: 37801135
doi: 10.1007/s00432-023-05444-0
pii: 10.1007/s00432-023-05444-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
17231-17239Subventions
Organisme : National Natural Science Foundation of China
ID : No.82203111
Organisme : National Natural Science Foundation of China
ID : No.82303879
Organisme : National Natural Science Foundation of China
ID : No. 82172579
Organisme : Science and Technology Planning Project of Guangzhou
ID : No. 2023A04J1777
Organisme : Science and Technology Planning Project of Guangzhou
ID : No. 2023A04J1781
Organisme : Clinical Trials Project (5010 Project) of Sun Yat-sen University
ID : No. 5010-2017009
Organisme : Clinical Trials Project (5010 Project) of Sun Yat-sen University
ID : No. 5010-2023001
Organisme : China Postdoctoral Science Foundation
ID : 2023M734035
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Bruix J, Reig M, Sherman M (2016) Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology 150:835–853. https://doi.org/10.1053/j.gastro.2015.12.041
doi: 10.1053/j.gastro.2015.12.041
pubmed: 26795574
Cheng A-L, Kang Y-K, Chen Z et al (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10:25–34. https://doi.org/10.1016/S1470-2045(08)70285-7
doi: 10.1016/S1470-2045(08)70285-7
Ding T, Xu J, Zhang Y et al (2011) Endothelium-coated tumor clusters are associated with poor prognosis and micrometastasis of hepatocellular carcinoma after resection: novel clinical role of microvessels. Cancer 117:4878–4889. https://doi.org/10.1002/cncr.26137
doi: 10.1002/cncr.26137
pubmed: 21480209
Fang J-H, Zhou H-C, Zhang C et al (2015) A novel vascular pattern promotes metastasis of hepatocellular carcinoma in an epithelial-mesenchymal transition-independent manner: hepatobiliary malignancies. Hepatology 62:452–465. https://doi.org/10.1002/hep.27760
doi: 10.1002/hep.27760
pubmed: 25711742
Fang J, Xu L, Shang L et al (2019) Vessels that encapsulate tumor clusters (VETC) pattern is a predictor of sorafenib benefit in patients with hepatocellular carcinoma. Hepatology 70:824–839. https://doi.org/10.1002/hep.30366
doi: 10.1002/hep.30366
pubmed: 30506570
Galle PR, Forner A, Llovet JM et al (2018) EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 69:182–236. https://doi.org/10.1016/j.jhep.2018.03.019
doi: 10.1016/j.jhep.2018.03.019
Goyal L, Zheng H, Abrams TA et al (2019) A phase II and biomarker study of sorafenib combined with modified FOLFOX in patients with advanced hepatocellular carcinoma. Clin Cancer Res 25:80–89. https://doi.org/10.1158/1078-0432.CCR-18-0847
doi: 10.1158/1078-0432.CCR-18-0847
pubmed: 30190369
He M-K, Le Y, Li Q-J et al (2017) Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study. Chin J Cancer 36:83. https://doi.org/10.1186/s40880-017-0251-2
doi: 10.1186/s40880-017-0251-2
pubmed: 29061175
pmcid: 5654007
He M-K, Zou R-H, Li Q-J et al (2018) Phase II study of sorafenib combined with concurrent hepatic arterial infusion of oxaliplatin, 5-fluorouracil and leucovorin for unresectable hepatocellular carcinoma with major portal vein thrombosis. Cardiovasc Intervent Radiol. https://doi.org/10.1007/s00270-017-1874-z
doi: 10.1007/s00270-017-1874-z
pubmed: 30073478
He M, Li Q, Zou R et al (2019) Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs sorafenib alone for hepatocellular carcinoma with portal vein invasion: a randomized clinical trial. JAMA Oncol 5:953. https://doi.org/10.1001/jamaoncol.2019.0250
doi: 10.1001/jamaoncol.2019.0250
pubmed: 31070690
pmcid: 6512278
Itoh S, Yoshizumi T, Yugawa K et al (2020) Impact of immune response on outcomes in hepatocellular carcinoma: association with vascular formation. Hepatology. https://doi.org/10.1002/hep.31206
doi: 10.1002/hep.31206
pubmed: 32112577
Iwai Y, Ishida M, Tanaka Y et al (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci 99:12293–12297. https://doi.org/10.1073/pnas.192461099
doi: 10.1073/pnas.192461099
pubmed: 12218188
pmcid: 129438
Kudo M, Finn RS, Qin S et al (2018) Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet 391:1163–1173. https://doi.org/10.1016/S0140-6736(18)30207-1
doi: 10.1016/S0140-6736(18)30207-1
pubmed: 29433850
Li Q-J, He M-K, Chen H-W et al (2022) Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: a randomized phase III trial. J Clin Oncol 40:150–160. https://doi.org/10.1200/JCO.21.00608
doi: 10.1200/JCO.21.00608
pubmed: 34648352
Lin W-P, Xing K-L, Fu J-C et al (2021) Development and validation of a model including distinct vascular patterns to estimate survival in hepatocellular carcinoma. JAMA Netw Open 4:e2125055. https://doi.org/10.1001/jamanetworkopen.2021.25055
doi: 10.1001/jamanetworkopen.2021.25055
pubmed: 34515782
pmcid: 8438596
Liu C-Q, Xu J, Zhou Z-G et al (2018) Expression patterns of programmed death ligand 1 correlate with different microenvironments and patient prognosis in hepatocellular carcinoma. Br J Cancer 119:80–88. https://doi.org/10.1038/s41416-018-0144-4
doi: 10.1038/s41416-018-0144-4
pubmed: 29921949
pmcid: 6035200
Llovet JM, Hilgard P, de Oliveira AC et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. https://doi.org/10.1056/NEJMoa0708857
doi: 10.1056/NEJMoa0708857
pubmed: 18923165
pmcid: 2963075
Lyu N, Kong Y, Mu L et al (2018a) Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma. J Hepatol 69:60–69. https://doi.org/10.1016/j.jhep.2018.02.008
doi: 10.1016/j.jhep.2018.02.008
pubmed: 29471013
Lyu N, Lin Y, Kong Y et al (2018b) FOXAI: a phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma. Gut 67:395.1-396. https://doi.org/10.1136/gutjnl-2017-314138
doi: 10.1136/gutjnl-2017-314138
Lyu N, Kong Y, Pan T et al (2019) Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin in hepatocellular cancer with extrahepatic spread. J Vasc Interv Radiol 30:349-357.e2. https://doi.org/10.1016/j.jvir.2018.09.004
doi: 10.1016/j.jvir.2018.09.004
pubmed: 30819477
Marrero JA, Kulik LM, Sirlin CB et al (2018) Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases: Marrero et al. Hepatology 68:723–750. https://doi.org/10.1002/hep.29913
doi: 10.1002/hep.29913
pubmed: 29624699
Qin S, Bai Y, Lim HY et al (2013) Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia. JCO 31:3501–3508. https://doi.org/10.1200/JCO.2012.44.5643
doi: 10.1200/JCO.2012.44.5643
Qin S, Cheng Y, Liang J et al (2014) Efficacy and safety of the FOLFOX4 regimen versus doxorubicin in chinese patients with advanced hepatocellular carcinoma: a subgroup analysis of the EACH study. Oncologist 19:1169–1178. https://doi.org/10.1634/theoncologist.2014-0190
doi: 10.1634/theoncologist.2014-0190
pubmed: 25223462
pmcid: 4221370
Renne SL, Woo HY, Allegra S et al (2020) Vessels encapsulating tumor clusters (VETC) is a powerful predictor of aggressive hepatocellular carcinoma. Hepatology 71:183–195. https://doi.org/10.1002/hep.30814
doi: 10.1002/hep.30814
pubmed: 31206715
Sugino T, Kawaguchi T, Suzuki T (1993) Sequential process of blood-borne lung metastases of spontaneous mammary carcinoma in C3H mice. Int J Cancer 55:141–147. https://doi.org/10.1002/ijc.2910550125
doi: 10.1002/ijc.2910550125
pubmed: 7688351
Sugino T, Kusakabe T, Hoshi N et al (2002) An invasion-independent pathway of blood-borne metastasis. Am J Pathol 160:1973–1980. https://doi.org/10.1016/S0002-9440(10)61147-9
doi: 10.1016/S0002-9440(10)61147-9
pubmed: 12057902
pmcid: 1850839
Sugino T, Yamaguchi T, Ogura G et al (2004) Morphological evidence for an invasion-independent metastasis pathway exists in multiple human cancers. BMC Med 2:9. https://doi.org/10.1186/1741-7015-2-9
doi: 10.1186/1741-7015-2-9
pubmed: 15066199
pmcid: 400511
Sugino T, Yamaguchi T, Hoshi N et al (2008) Sinusoidal tumor angiogenesis is a key component in hepatocellular carcinoma metastasis. Clin Exp Metastasis 25:835–841. https://doi.org/10.1007/s10585-008-9199-6
doi: 10.1007/s10585-008-9199-6
pubmed: 18712609
pmcid: 3431607
Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA A Cancer J Clin 71:209–249. https://doi.org/10.3322/caac.21660
doi: 10.3322/caac.21660
Zhu AX (2006) Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be? Oncologist 11:790–800. https://doi.org/10.1634/theoncologist.11-7-790
doi: 10.1634/theoncologist.11-7-790
pubmed: 16880238